Detalhe da pesquisa
1.
Chemoradiotherapy for untreated Masaoka-Koga stage IVB thymic carcinoma: a single-center retrospective study.
Strahlenther Onkol
; 199(3): 313-321, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729136
2.
Predicting the efficacy of immune checkpoint inhibitors monotherapy in advanced non-small cell lung cancer: a machine learning method based on multidimensional data.
Neoplasma
; 70(2): 300-310, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36812231
3.
Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer.
Neoplasma
; 69(4): 976-982, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603955
4.
The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study.
Neoplasma
; 69(6): 1437-1444, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36353935
5.
Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses.
Cancer
; 126(4): 840-849, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31714592
6.
Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.
J Transl Med
; 16(1): 93, 2018 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29642919
7.
Definitive local therapy for extracranial single-organ oligorecurrent non-small-cell lung cancer: A single institutional retrospective study.
Medicine (Baltimore)
; 101(46): e31918, 2022 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36401441
8.
A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Chemotherapy
; 56(6): 472-7, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21099219
9.
Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Lung Cancer
; 139: 118-123, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31775086
10.
A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib.
Cancer Biol Ther
; 19(12): 1097-1101, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30095326
11.
EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
Lung Cancer
; 115: 131-134, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29290255
12.
MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma.
J Thorac Oncol
; 13(10): e202-e204, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30244854
13.
Preoperative elevation of serum C-reactive protein as an indicator of poor prognosis for early-stage esophageal squamous cell carcinoma.
Kaohsiung J Med Sci
; 29(12): 662-6, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24296054
14.
Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib.
J Thorac Dis
; 10(5): E359-E363, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29997994
15.
Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
Lung Cancer
; 121: 101-104, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29773459
16.
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.
Chin Med J (Engl)
; 124(15): 2279-83, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21933557